Lifesciences

The Indian life sciences industry contributes significantly to the Indian economy, bolstering the country’s intrinsic strengths in vaccine manufacturing, generic drugs, and biopharma. With a current market of USD 42 billion, projected to be USD 130 billion by 2030, India is dominating the global market as the largest manufacturer of affordable generic medicines. Over the last couple of years, there has been a trend of investments in research and development, manufacturing, digital data management, artificial intelligence and machine learning to treat and track lifestyle diseases. There is an upsurge in health tech start-ups in the country. The market has caught the eye of international investors who want to ride the wave as well.

The sector remains under constant scrutiny with regards to promotional interactions, clinical trials and other aspects. Given the incredible rate of growth, the industry continues to be heavily supervised with stringent regulations.

Trilegal’s life sciences practice is equipped to handle such complexities for clients. The practice comprises lawyers who hold extensive expertise in acting for businesses and investors across segments of the industry, including in biotech, diagnostics, biopharma and genetics. Our practice routinely handles cross-border cases in the sector and has led mergers and acquisitions, commercial transactions, contentious and non-contentious intellectual property matters, digital transformation, strategy and operations, and financings. The team has helped clients successfully devise/reinvent their litigation strategies to mitigate risks and navigate regulatory and compliance challenges.

Some of our clients in this space include-

• Strand Life Sciences
• IHH Healthcare Berhad
• Apollo Hospitals
• Max Healthcare Institute
• Novartis Diagnostics
• Quest Diagnostics
• Manipal Health Enterprises
• GE Healthcare
• Jubilant Biosys
• Glenmark Pharmaceuticals
• Piramal Pharma
• J.B. Chemicals and Pharmaceuticals